The findings, presented at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Annual Symposium and ...

The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.

Marwan G. Fakih, MD, discussed the implications of the findings from the phase 2 study for patients with microsatellite ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Researchers reported overall response rates of 78% for all patients in the phase 2 portion, 80% for those who received the recommended phase 2 dose, and 61% for those with extramedullary disease.